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Abstract
The ultimate goal of drug design is to find novel compounds with desirable phar-
macological properties. Designing molecules retaining particular scaffolds as the core
structures of the molecules is one of the efficient ways to obtain potential drug can-
didates with desirable properties. We proposed a scaffold-based molecular generative
model for scaffold-based drug discovery, which performs molecule generation based on
a wide spectrum of scaffold definitions, including BM-scaffolds, cyclic skeletons, as well
as scaffolds with specifications on side-chain properties. The model can generalize the
learned chemical rules of adding atoms and bonds to a given scaffold. Furthermore, the
generated compounds were evaluated by molecular docking in DRD2 targets and the
results demonstrated that this approach can be effectively applied to solve several drug
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design problems, including the generation of compounds containing a given scaffold and
de novo drug design of potential drug candidates with specific docking scores.
1 Introduction
"Molecular scaffold" is one of the most important and widely used concepts in medicinal
chemistry. Given a chemical compound, its "scaffold" generally represents the core structures
of the molecular framework.1 Although various definitions of molecular scaffolds are available,
the most widely adopted version is given by Bemis and Murcko,2 who obtain the scaffold by
removing all side chains (or R-groups). Among all scaffolds, those with preferable bioactivity
properties (which are referred to as "privileged scaffolds"3 or "bioactive scaffolds"4,5) are of
particular interest to drug discovery. Privileged scaffolds are often used as a starting point
for compound synthesis or diversification. Previous researches have developed various types
of tools to extract and utilize information from scaffolds, including tools for the discovery
of privileged scaffolds (such as CSE6 and5), tools for organizing scaffolds (such as HierS,7
SCONP,8 ST9 and SN4), as well as tools for visualization (such as Scaffold Hunter10).
Recently, deep learning11 have revealed itself as a new and promising tool for many drug-
design-related problems. In particular, there is a growing interest in using deep generative
models12 for de novo molecule design.13 Early works in this area14–16 mainly utilizes RNN
based architectures (such as GRU16 or LSTM14) to generate SMILES strings,17 which is a
serialized representation of molecules graph. Those methods have proven to be very effective
for de novo molecule design, but still faces certain issues, such as the need to learn SMILES
gramma. Recent works18–22 have improved upon this approach by using graph-based rep-
resentations of molecules. Also, other types of generative architecture have been explored,
such as GAN.23 Those models have been successfully applied to various drug design prob-
lems, such as the property-based design of virtual libraries,16,18 ligand14,16,18 and structural24
based drug design, as well as local optimization of molecular structures.16,22
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With the promising performance, it is natural to apply deep generative models to scaffold
directed drug design. Early works have used conditional generative model,18 reinforcement
learning18 or transfer learning25 to achieve molecule generation based on scaffold queries.
However, those methods do not guarantee that the outputs molecule will match the input
query, and are difficult to be extended to new scaffolds. A recent publication by Lim et. al.26
solved the problems above using a model that directly grow molecules on the given scaffold.
However, the model is restricted only to BM-scaffolds, which does not necessarily fit well
with all tasks in medicinal chemistry.
In this work, we introduce DeepScaffold, a novel and comprehensive solution for scaffold-
based drug discovery. Different from previous methods, DeepScaffold can perform molecule
generation based on a wide spectrum of scaffold definitions, including BM-scaffolds, cyclic
skeletons, as well as scaffolds with specifications on side-chain properties. Our proposed
method can guarantee that the output molecule would match the scaffold query, and can
be easily extended to new scaffolds outside the training set. A broad set of evaluation is
carried out to access the performance of DeepScaffold. We also discuss several challenges
faced when evaluating such scaffold-based generative models.
2 Methods
2.1 An overview of DeepScaffold
Before diving into the implementation details, we first take a look at the overall architecture
of DeepScaffold. As mentioned earlier, DeepScaffold is capable of performing de novo drug
design based on the following scaffold definitions (Figure1):
• Cyclic skeletons
• Scaffolds with atom and bond type information, such as Bemis-Murko scaffold
• Scaffolds with additional specification on side-chain properties
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Figure 1: An overview of DeepScaffold. DeepScaffold is a comprehensive tool for scaffold-
directed drug discovery, capable of performing molecule generation based on a. cyclic skele-
tons (CSKs), b. classical molecular scaffolds, such as Bemis-Murko scaffolds, as well as c.
scaffolds with additional pharmacophore-based queries for side chains.
For convenience, we refer to the first type of structures as the “skeletons”, and the second
type of structure as the “classical scaffolds”. To achieve those functionalities, DeepScaffold
is composed of the following three components:
• A neural network for completing atom and bond type for cyclic skeletons (Figure 2a)
• A scaffold-based molecule generator (Figure 2b)
• A filter for side-chain properties based on pharmacophore queries (Figure 2c)
The three components are discussed in detail in the rest part of this section. We first
discuss the dataset and data processing workflow in Section 2.2.The transformer from skele-
tons to scaffolds is discussed in Section 2.3, and the scaffold-based generator is discussed
in Section 2.4. We briefly discuss the pharmacophore quires in 2.5 Finally, the evaluation
methods are discussed in Section 2.6.
2.2 Dataset
For model training, we use molecules from ChEMBL,27 which is a widely used database
containing both structural and bioactivity information for molecules. The data processing
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Figure 2: The basic components for DeepScaffold. As shown in the figure, DeepScaffold is
composed of the following three models: a. A neural network for completing atom and bond
type for cyclic skeletons; b. A scaffold-based molecule generative model; c. A filter based
on side-chain properties
workflow largely follows that used in our previous study.18 First of all, the structural in-
formation of molecules represented as canonical SMILES are first extracted from ChEMBL
dataset. The molecules are then standardized using RDKit, which involves the removal of
salt and isotopes, as well as charge neutralization. Molecules containing elements outside
the set {H, C, N, O, F, P, S, Cl, Br, I} are filtered from the dataset. Also, to make the
dataset more suitable for drug design purposes, we only keep molecules with QED28 larger
than 0.5. The final dataset (denoted as M = {mi}Nmi=1) contains Nm = 914464 molecules.
The distribution of several important molecular properties (including MW, LogP, QED and
SAscore29) are visualized in Figure 3.
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Figure 3: a-d. The distribution of several important molecular properties (a for MW, b for
LogP, c for QED, d for SAscore) of the extracted molecules. e. Workflow for scaffold extrac-
tion. Given the input molecule, the Bemis-Murcko scaffold is first extracted by removing all
side chains. Other scaffolds are then obtained by recursively removing ring systems.
After the dataset is obtained, we need to extract scaffolds from each molecule. Previous
researchers have developed many different ways to extract and organize scaffolds from struc-
tural data. Examples include HierS,7 SCONP,8 scaffold tree (ST)9 and scaffold network
(SN).4 Here, we adopt the same scaffold extraction method as HierS. Compared with ST
and SN, which are more widely adopted, HierS results in a fewer amount scaffolds, but is
much easier to implement.
Molecules are composed of three components: ring systems (ring), side-chain bonds and
atoms (chain), and linking bonds and atoms (linker). Atoms that are external to a ring but
are bonded to a ring atom with a bond order greater than 1 are to be part of the ring system
because they modify the nature of the ring. Atoms that are double-bonded to linker atoms
are also considered to be part of the linker because they can modify the nature of the linker.
The basis scaffolds for a molecule are the set of all unique ring systems in the molecule,
where a ring system is defined as one or more rings that share an internal bond.
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Figure 4: Formal charges are removed and explicit hydrogen atoms are fixed after removing
chains connected with nitrogen atoms in aromatic rings.
A recursive algorithm is used to elucidate all candidate scaffold structures including those
derived from exhaustive combinations of the basis scaffolds. It recursively removes each ring
system from the scaffolds of each level to generate fragments that contain all possible ring
system combinations. Finally, the process is completed by adding the Bemis-Murko scaffold
of the compound to the list of scaffold structures.
While removing chains/linkers connected on nitrogen atoms in aromatic rings, things
become a little complicated. We have two choices to keep a molecule in correct valence
while fracturing such bonds (Figure 4). It’s not in line with common sense about molecular
scaffolds if a supplied scaffold has charges on some atom in it. Therefore we select the process
above in Figure 4 to get the scaffold without any bonds connected with nitrogen atoms in
aromatic rings, which can be an initiation point in the scaffold-based generative model. The
indices of processed nitrogen atoms in each molecule are recorded in the scaffold extraction
workflow as well, so as to modify it while generating a molecule.
After all the distinct basis and multi-ring system scaffolds for each molecule have been
identified and added to the scaffold list, hierarchical structural relationships between the
scaffolds (s ∈ S) and original compound (m ∈ M) structures are established. Once all
scaffolds are identified and their hierarchical relationships are established, the process can
rapidly traverse the network of structural connections to determine relationships between
indices of scaffolds and its original compounds.
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Finally, to facilitate the sampling of training data during model optimization, we created
indexes between skeletons (c ∈ C), scaffolds (s ∈ S) and molecules (m ∈ M). Specifically,
indices are created:
• From a given scaffold s to its corresponding skeleton c(s).
• From a given scaffold s to the set of all molecules containing that scaffoldM(s)
• From a given molecule m to the set of its sub-scaffolds S(m)
2.3 Generating scaffolds from cyclic skeletons
As discussed in Section 2.1, to generate molecules from a given cyclic skeleton (CSK), we
need to first generate a scaffold with atom types and bond types. To achieve this goal, we
need to model a conditional distribution pθ(Gs|Gc), where Gc is the molecular graph of CSK
c, and Gs is the graph of the classical scaffold s.
2.3.1 The generative model
We construct the generation process as follows (see Figure 5):
• We first attach to each node v and edge e in c a latent variable sampled from a prior
distribution v, e ∼ pθ(|Gc). Here, we use a gaussian distribution with diagonal co-
variance structure to parameterize the prior: pθ(|Gc) = N (;µpriorθ (Gc),σpriorθ (Gc)2I)
• The latent variables v, e, together with the topological structure of the CSK, is fed
into a graph convolutional neural network to generate a probability distribution of
atom types for each node pv and bond types for each edge pe.
• The types of each atom and bond in the output scaffold s are then sampled from the
distributions pv and pe.
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Figure 5: The architecture of the model to transform CSKs to classicial scaffolds. Under
the context of autoencoder, the entire model contains three components: the encoder, the
decoder, and the prior network. During training, the reconstruction loss Lrecon and the KL
loss LKL are calculated using the encoder, decoder and prior for model optimization. During
inference, the latent variable is first sampled from the prior network and then fed into the
decoder (or the generator network) to produce the classical scaffold.
The latent variables are necessary to capture the probabilistic dependencies between
different atoms and bonds. For convenience, we let V = [v]v∈V , E = [e]e∈E, and  =
[V , E]. Under the construction above, we can write the conditional distribution pθ(Gs|Gc)
as:
pθ(Gs|Gc) =
∫

pθ(Gs|Gc, )pθ(|Gc) (1)
2.3.2 Variational auto-encoder
A straight forward way of training such models is to maximize its likelihood value. However,
as the model contains latent variables, calculating its likelihood value is not directly feasible.
Therefore, we use variational inference to obtain a lower-bound of the likelihood. Specifically,
we reformulate the model as a variational autoencoder30 by adding an auxiliary inference
network qθ(|Gs, Gc) to the model. Since Gs already contains the full information of Gc,
we shall write the inference network as qθ(|Gs). Similar to the prior, we use a diagonal
Gaussian distribution for qθ: qθ(|Gs) = N (;µpostθ (Gs),σpostθ (Gs)2I). In the context of
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Figure 6: The architecture of the graph convolutional neural network (GNN). Before feeding
into the GNN, two transformations are performed on the original molecular graph G: a.
Virtual bonds are added to capture remote connectivity relationship. b. The atoms and
bonds are treated equally as "nodes" in the new graph. c. Adding a hierarchical organization
to the molecular graph
autoencoders, the generator pθ is often referred to as "decoder", and the inference network
qθ the "encoder". We then obtain the loss function as follows:
L(θ) = −E∼qθ [log pθ(Gs|Gc, )] +KL(p()||qθ(|Gs, Gc)) (2)
The first term and second term in eq.2 are usually called the reconstruction loss (Lrecon)
and the KL loss (LKL) respectively. Minimizing the loss eq.2 is maximizing a lower bound
on the likelihood function eq.1.
2.3.3 Graph convolutional neural network
The encoder qθ(|Gs), decoder pθ(Gs|Gc, ), as well as the prior network pθ(|Gc) are all
parameterized using graph convolutional neural networks (GNN). The architecture is shown
in Figure 6.
Before entering the graph convolutional network, we perform the following transforma-
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tions to the input graph G = (V,E):
• Virtual bonds are added to capture remote connectivity relationship. Specifically,
we add new bonds between atom pairs separated by two or three bonds, similar to
our previous works.18 We also create new bond types for those virtual connections to
separated them from real chemical bonds. The molecular graph with virual bonds are
denoted as G(1) = (V (1), E(1)).
• G(1) is then transformed into a new graph G(2) = (V (2), E(2)) by treating atoms and
bonds in G(1) equally as nodes in G(2). In other words, we have V (2) = V (1)∪E(1), and
E(2) = {{v, e}|v ∈ V (1), e ∈ E(1) and v ∈ e}.
• For each ring R in the graph G, we add a virtual node vR to the G(2), and connect it to
each element inside the ring R in graph G(2). Similar operations are performed for each
linker in G. In terms of ring assemblies, virtual nodes are added and are connected
to virtual elements representing rings. The overall effect is shown in Figure 6c.. The
transformed graph is denoted as G(3) = (V (3), E(3))
After those transformations, the graph G(3) is then sent to the graph convolutional net-
work as input. Each convolution operation is composed of three stages:
• Broadcasting: The information of nodes are broadcasted to edges. Specifically, for
each edge e = {u, v} ∈ E(3), the representation of terminal nodes hu and hv are
broadcasted to edge e as
he = MLPbroadcast([hu,hv]) (3)
[·, ·] is the concatenation operation for vectors. MLPbroadcast is a linear layer with
BN-ReLU-Linear architecture.
• Gathering: The information broadcasted to each edge is again gathered to each node.
We use to ways to gather information from edges: summation and maximization. The
edge representation is firstly split into two parts:
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[hmaxe ,h
sum
e ] = he (4)
vectors hmaxe are subjected to maximization:
hmaxv = max
e∈E(3)andv∈e
hmaxe (5)
vectors hsume are subjected to summation:
hsumv =
∑
e∈E(3)andv∈e
hsume (6)
The results are concatenated:
hgatherv = [h
max
v ,h
sum
v ] (7)
• Updating: The representation of each node is updated using the gathered information:
hnewv = MLP
update([hv,h
gather
v ]) (8)
MLPupdate is a linear layer similar to MLPbroadcast
2.3.4 Training details
The model is validated using the holdout method. 80% of scaffolds are used for training
(denoted as Strain), and the remaining 20% is used for testing (denoted as Stest). The
metrics used for test set evaluation is discussed in detail in Section 2.6.1. The mini-batches
B = {si, ci}|B|i=1 used at each step for model training is constructed by first sampling the
scaffolds ({si}|B|i=1) are then finding their corresponding cyclic skeleton ci = C(si). Naive VAE
tends to suffer from the problem of posterior collapse. To encourage the model to encode
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more information into the latent variable, we experimented several attempts, including KL-
annealing (proposed in31) and β-VAE (proposed in32).
AdaBound is used for model optimization, with the initial learning rate set as 1× 10−3,
and the final learning rate as 0.1. This means that the optimizer will gradually anneal from
an Adam optimizer with learning rate 1 × 10−3 to an SGD optimizer with learning rate
0.1. The gradient is clipped to [-3, 3] to improve model stability. The dimension of latent
variables v, e is set to be 10. We performed experiments with more latent variables, but
found little improvement in model performance.
2.4 Scaffold-based molecule generation
Now we introduce the model used for scaffold derivatization. The central goal of this task is
to reconstruct the side-chains based on the structural information of the scaffold. Formally
speaking, we are modeling the conditional distribution pθ(x|s), where s is the scaffold and x
is the full molecule. The generation process of side-chain follows largely from our previous
work.18 The major difference is that for scaffold-based generation, the process starts from
the graph of the given scaffold, instead of an empty graph (see Figure 7). The model builds
the molecule in a step-by-step fashion. At each step, the model needs to decide which of the
following actions to perform: (1) append a new atom to the graph, (2) connecting two existing
nodes or (3) to terminate the generation process. The architecture of graph convolutional
layer is similar to that used in.18 In terms of the model architecture, a 20 layer densenet is
used in this model, similar to Section 2.3. The growth rate is set to 24, and the number
of features in each bottleneck layer is set to 96. We use the likelihood-based loss function
for model optimization. Importance sampling is used to improve the performance of the
model (following18). The value for the hyperparameter k (the number of samples generated
from importance sampling) and α (parameter controlling the degree of uncertainty in route
sampling) is set as 5 and 0.5 respectively.
Note that our proposed model share similarity with that by Lim et. al. Both methods
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share the idea of growing the molecule directly from the scaffold. However, we improve upon
the work by Lim et. al. from the following perspectives:
• Beside including Bemis-Murko scaffolds of molecules, we also included all its sub-
scaffolds within our dataset (under the definition of HierS, see Section 2.2 for details).
This treatment will have two advantages for the model.
– First of all, expanding the scaffold set S will reduce the chance of missing potential
bioactive scaffolds, making the dataset more fitted to the practical need.
– Secondly, the definition of Bemis-Murko scaffold has excluded all ring-based struc-
tures from the side-chain, making it overly restricted for situations in medicinal
chemistry. By including the sub-scaffolds, we can significantly increase the struc-
tural diversity of the substituents in the scaffold, thereby expanding the practi-
cality of our model.
• Compared with Lim et. al., we include a much wider range of metrics for model
evaluation (see 2.6), including MMD, internal diversity, docking score and so on. We
also include case studies related to scaffold-based drug discovery for GPCRs.
Model validation is performed in the following two ways:
2.4.1 Holdout validation
Holdout method is mainly used to obtain an overall view of the model’s performance. The
set of all molecules is split into two portions: the training set (80%) and the test set (20%),
used respectively for model optimization and evaluation. Note that is method will result
in an overlap of scaffold set between the training and test set, therefore can not be used to
examine the model’s ability to generalize to new scaffolds.
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Figure 7: The generation process. a. Unconditional generative models (such as MolMP)
starts molecule generation from empty graph G0 = (, ). b. DeepScaffold starts molecule
generation directly from scaffolds.
2.4.2 Leave-one-out validation
Leave-one-out validation is carried out in the following way: Given a scaffold of interest, we
gather all molecules containing this scaffold as substructure, and exclude those molecules
from the training set. Following this method, there will be no overlap of scaffolds and
molecules between training and test set. However, it is impractical to perform such validation
to all 338,932 extracted scaffolds. Therefore, we selected three scaffolds as a case study, as
shown in Figure 13. All scaffolds selected are privileged scaffolds for G-protein-coupled
receptors (GPCRs) .
Model optimization is performed using Adam optimizer. The learning rate is set to 0.001
in the first step, and decay at a rate of 0.99 for every 100 steps, until the minimum learning
rate 5 × 10−5 is reached. Regularization techniques such as dropout or weight decay are
not used in this model. To stabilize training, the gradient is clipped to [-3.0, 3.0] at each
optimization step. Training is performed for 50,000 iterations, taking roughly 20 hours to
complete.
At each step, we need to sample a mini-batch of scaffold-molecule pairs (B = {si,mi}|B|i=1)
from the training set. The batch size |B| is set to 128. Note that there are many different
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ways to perform the sampling from the training set. For example, we can first sample a set of
scaffolds {si}|B|i=1 and then assign each scaffold si with a molecule drawn from M(si). We can
also sample molecule first and scaffold next. The impact of different sampling algorithm is
analyzed in Supporting Information. The result can be summarized as follows: (1) If we place
equal weight to each scaffold, the molecules will be sampled disproportionately. (2) If we
place equal weight to each molecule, the scaffolds will then be sampled disproportionately. In
a word, it is quite difficult to balance both scaffold and molecule. As a result, we construct
each mini-batch using a mixture of samples from both sampling methods. Here, we use
equal weights for each sampling method. In future works, the weight can be treated as a
hyperparameter and be subjected to optimization and tuning.
2.5 Using scaffold and pharmacophore as queries for generation
For medicinal chemists, it is would often be useful to have the ability to specify the property
of substituents at specific locations during scaffold-based molecule design. This may happen
when we have clear SAR information concerning the given scaffold. In this work, we also
created a tool to use both scaffold and pharmacophore queries during molecule generation.
The implementation of this functionality is rather simple: after the molecules are generated
from the scaffold using the method discussed in Section 2.4, we filter those results against the
user’s queries. We currently allow users to specify the size of the side-chain (measured using
the number of heavy atoms ), whether to have hydrogen bond donors (HBD) and whether
to have hydrogen bond acceptors (HBA). We plan to increase the spectrum of supported
queries in the future.
2.6 Evaluation
2.6.1 Generating scaffolds from cyclic skeletons
We use the following metrics for model evaluation:
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Reconstruction loss, KL loss and total loss VAE learn the generative model by
trying the achieve the best reconstruction using the least information. The reconstruction
loss Lrecon measures the accuracy of reconstruction for the autoencoder, while the KL loss
LKL measures the amount of information stored inside the latent variable. The total loss
Ltotal, which is also used during the model training, is the sum of reconstruction loss and
KL loss.
Chemical validity Given a cyclic skeleton c, we measure the chemical validity of output
scaffolds generated from skeleton c. The validity of a given molecule is evaluated using the
Chem.Sanitize API provided by RDKit. The validity is measured by the percent valid
output calculated as follows:
P validc = N
valid
c /N
total
c (9)
where Nvalidc is the number of valid outputs and N totalc is the number of total outputs.
Those values are averaged among all cyclic skeletons, and the final value P¯valid is reported.
2.6.2 Evaluating scaffold-diversification model
In order to evaluate the performance of the scaffold-based molecular diversification model,
we gather all scaffolds occurred inside the test set, and remove those with less than 10
corresponding molecules. After obtaining the set of scaffolds to be evaluated (denoted as
Stest), 10,000 sample molecules are generated for each scaffold, and the evaluation of those
samples is carried out using the following metrics.
Chemical validity and uniquenessWe first measure the chemical validity and unique-
ness of the generated molecules. The validity of a given molecule is evaluated using the
Chem.Sanitize API provided by RDKit. For a given scaffold s, we obtaining the number of
valid outputs (denoted as Nvalids ), and divide it with the total number of generated molecules
(denoted as N totals ). The percentage of valid outputs are calculated using eq.10.
To calculate the uniqueness, we remove all duplicated molecules from the valid outputs,
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and calculate the number of remaining molecules (denoted as Nuniqs ). The uniqueness is
calculated using eq.11.
P valids = N
valid
s /N
total
s (10)
P uniqs = N
uniq
s /N
valid
s (11)
P valids and P uniqs scores are calculated for each scaffold inside the test dataset, and the
average values of the two metrics (P¯valid and P¯uniq) are reported. The distribution of the two
metrics among all test set scaffolds is also reported. Also, we will discuss how scaffold sizes
would affect those two performance metrics.
Distribution of molecular properties Next, we investigate the model’s ability to
correctly model the distribution of several important molecular properties. Here we consider
the following three properties: molecular weight (denoted as MW ), log partition coefficient
(denoted as logP ) and the drug-likeness score (measured by QED28). All properties above
can be calculated using RDKit.
For each scaffold s in the test set, we compare the mean and standard deviation of each
property (MW , logP and QED) between the molecules generated and molecules in the test
set. Previous studies have used metrics such as DKL and DJD to quantify the difference. The
approach adopted here is simpler, but offers higher interpretability compared with DKL and
DJD. For a quantitative evaluation, we instead use maximum mean discrepancy (MMD), as
discussed in Section 2.6.2.
Diversity Output diversity is another important metric for evaluating molecular gener-
ative models. Although, as discussed in Section 2.6.2, the standard deviation of molecular
properties could, in some extent, reflect the structural diversity of the generated outputs, a
more rigorous definition of structural diversity is needed for quantitative evaluation. Here,
we adopt the formulation of internal diversity proposed by Benhenda et. al.33 Supposed the
molecules are sampled from a molecule distribution x ∼ p(x), the structural diversity of this
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distribution can be defined as:
I = 1− E
x,y∼p
[k(x, y)] (12)
Where k(x, y) is the similarity of the two molecules x and y. Here, we use the tanimoto
score of the Morgan fingerprints between the two molecules as the similarity measurement.
Intuitively speaking, the structural diversity of p is defined as one minus the average similarity
between two randomly sampled molecules from p. We can estimate the value of I from
samples {xi}Ni=1 drawn from p:
IˆU = 1−
∑N
i=1
∑N
j=1,j 6=i k(xi, xj)
N(N − 1) (13)
It can be proved that IˆU is an unbiased estimator of I. Note that this estimator is slightly
different from that originally proposed by Benhenda et. al.:33
IˆV = 1−
∑N
i,j=1 k(xi, xj)
N2
(14)
It can be shown that IˆV is equals to N−1N IˆU , and therefor a biased V-staticstics for I.
Also, it can be shown that the bias of IˆV depends on the sample size N , and will be larger
in smaller datasets. This could be problematic for two ways: First, many scaffolds in the
test set have only a small number of corresponding molecules, which may increase the bias.
Second, the sample size (N) of the test set is usually smaller than that of the generated
samples, which will bring additional bias to the result. Therefore, the U-statistics IˆU is
instead used in this paper for the calculation of internal diversity.
Maximum mean discrepancy (MMD) The central task of scaffold-based diversifica-
tion is to model the conditional distribution p(x|s) of molecular structure x given the scaffold
s. Therefore, the most natural way of evaluating such models would be measuring the dissim-
ilarity between the ground truth distribution pd(x|s) and the modeled distribution pg(x|s).
Maximum mean discrepancy (MMD) is one of such metrics that have been widely applied
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in generative modeling (both for model training34 and evaluation35). Different from other
metrics, such as Jensen–Shannon divergence (JSD), Wasserstein distance (WD)36 or Frechet
ChemNet distance (FCD),37 MMD does not require additional discriminator or preditor to
be evaluated, which makes it much easier to calculate.
Given the samples from two probability distribution {xi}Ni=1 ∼ pd, {yi}Mi=1 ∼ pg, the
MMD between the two distribution can be estimated as:
Dˆ =
1
N(N − 1)
N∑
i=1
N∑
j=1,j 6=i
k(xi, xj) +
1
M(M − 1)
M∑
i=1
M∑
j=1,j 6=i
k(yi, yj)− 2
MN
N∑
i=1
M∑
j=1
k(xi, yj)
(15)
Where k(·, ·) is the kernel function. Similar to Section 2.6.2, we choose the tanimoto
similarity between molecules as k. It can be proved that tanimoto similarity is in fact a
legitimate kernel function.38
One of the most important applications the model is the design of molecule-based on
privileged scaffolds. Ideally, given a known bioactive scaffold, the generated molecule should
also be bioactive. To test whether the model possess such desirable property, we examine:
• The ability for the generative model to reproduce known active molecules
• The (predicted) bioactivity of the output molecules for the target.
The rate of reproduced active compounds First of all, the rate reproduced active
molecules (denoted as R) for GPCRs is reported. Specifically, we collect all molecules that
are active against at least one target in the GPCR family (denoted as the set TGPCR), and
examine how many of them appear in the set of molecules sampled from the model(denoted
as Ms):
RGPCR =
|Ms ∩ TGPCR|
|TGPCR| (16)
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We also investigate the ability for the model to reproduce known drugs, by collecting all
drugs (denoted as Tdrug) from the test set, and calculate the ratio Rdrug:
Rdrug =
|Ms ∩ Tdrug|
|Tdrug| (17)
Docking Next, we report the predicted activity of output molecule for GPCRs. It is
impractical to evaluate the output molecule against all targets in the GPCR family. Instead,
we choose Dopamine Receptor D2 (DRD2) as a representative, which is a well-studied target
for antipsychotic drugs.39 The predicted activity for DRD2 is calculated using docking. The
bioactivity model for DRD2 is built following Supporting Information:
For each bioactive scaffold selected for GPCRs, a comparison of docking scores was carried
out between four sets of compounds: (1) samples generated by the model, (2) molecules inside
the test set, (3) known actives for DRD2 and (4) randomly sampled molecules from ChEMBL.
A well-performing generative model should result in a similar distribution of docking scores
between (1) and (2). Also, the average score for (1) should be close to (3), and better than
(4).
Structural distribution of side-chains Given the set of generated molecules given
a scaffold, users can further filter the result by adding requirement on the properties of
side-chains attached to the scaffold. Since different users may require different types of
substitution in different locations, the model needs to generate a diverse set of side-chain
configurations in order to handle the user’s requirements efficiently. Therefore, for each
scaffold in the leave-one-out evaluation (see Section 2.4.2), we analyze the location and size
of each side-chain in the generated molecules in order to evaluate the diversity of side-chains.
We also compare the result with test set molecules to determine the quality of the generated
samples.
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3 Results
3.1 Generated samples
Before diving into model’s performance, we present a brief view of DeepScaffold by showcas-
ing several generated molecules from cyclic skeletons as well as classical scaffolds using the
model. The result is demonstrated in Figure 8. Two cyclic skeletons, scaffold 4 (Figure 8
g), with a relatively simple structure, as well as the more complexed scaffold 1 (Figure 8 b),
are selected from the hold-out test set. For each scaffold, we generate two classical scaffolds
(scaffold 2 (Figure 8 c) and scaffold 3 (Figure 8 e) for scaffold 1, as well as scaffold 5 (Figure
8 h) and scaffold 6 (Figure 8 j) for scaffold 4 and structural derivification is performed on
those structures (Figure 8 d,f,i,k).
Figure 8: Generated samples from DeepScaffold.
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3.2 Generating scaffolds from cyclic skeletons
The performance of the proposed model is evaluated following Section 2.6.1, with results
shown in Table 1.
First of all, it is shown that approaches such as KL-annealing and β-VAE all showed
positive results in solving posterior collapse. Both VAE + annealing and β-VAE are capable
of achieving higher LKL. Notably, by using annealing, the model can achieve a slightly better
Ltotal with a much higher LKL. In terms of the output validity, β-VAE (with β value set
to 0.5) can achieve the best performance of 82.5%. Interestingly, the output validity is not
always consistent with the performance measured using Ltotal. In the future, we plan to
utilize more recent techniques in VAE training in order to improve the result, such as using
more complexed prior40 posterior.41
Table 1: Generating scaffolds from cyclic skeletons
Model %valid %recon LKL Lrecon Ltotal
β-VAE (β = 0.5) 82.50% 61.00% 9.82 1.11 10.93
β-VAE (β = 0.1) 80.70% 91.30% 14.15 0.23 14.38
VAE + KL annealing 76.80% 10.00% 5.02 4.38 9.4
VAE 68.50% 6.32% 3.37 6.06 9.43
3.3 Scaffold derivation
3.3.1 Validity and uniqueness
The performance of scaffold-based molecular diversification in terms of validity and unique-
ness is summarized in Figure 9. Among all scaffolds, the average percentage of valid output
(P¯valid) is 98.9%, and the average percentage of unique output is 69.1% (P¯uniq), as shown in
Figure 9. It is immediately noticed that the result in P¯valid and P¯uniq is significantly different
from the results produced by the unconditional version of the model with similar architec-
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Figure 9: Sample validity and uniqueness. a. The average validity (98.8%) and uniqueness
(69.1%) among all scaffolds. b. The relationship between the molecular weight of each
scaffold and the (logit) precent-valid output. c. The relationship between molecular weight
for each scaffold and (logit) percent unique output. d-e. Several generated samples using
scaffolds with d. high molecular weight and e. low molecular weight.
ture.18 Specifically, the scaffold-based model can achieve a higher precent-valid value, while
having a lower percent unique value. A similar result was reported by Lim et. al.26 using a
different dataset including BM scaffolds.
To better understand the phenomenon, we further investigate the relationship between
the scaffold size (measured by the molecular weight of the scaffoldMWs) and the performance
of the two metrics. The result is shown in Figure 9 and Figure 9. It can be shown thatMWs
is positively correlated with P valids (correlation coefficient r =0.73, significance level p < 0.001
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), while negatively correlates with P uniqs (correlation coefficient r =-0.66, significance level
p < 0.001). This means that larger scaffolds tend to have higher output validity, but lower
uniqueness. The result is in fact inline with the mode of thinking in medicinal chemistry:
for smaller scaffold, there is usually a plenty of room for structural diversification, while for
larger scaffolds, in order to achieve higher drug-likeness and synthetic accessibility, the size
and diversity of structural modification are much more restricted, resulting in a higher chance
of duplicates. Also, smaller side-chains means fewer generation steps, which will, therefore,
reduce the chance of validity violation during generation. Two representative scaffolds are
chosen from the test scaffold set and are shown in Figure 9 and Figure 9. Consistent with the
analysis above, the side-chains attached to the smaller scaffold is larger and more diverse,
and those attached to the larger scaffold have a much simpler structure.
The discussion above also provides some important insight into how future benchmarks
should be constructed for this type of model. First of all, since the evaluation metrics such
as P valids and P uniqs depends on the scaffold s chosen for evaluation, it is important to use a
common scaffold set as the test set during model comparisons. Secondly, it will be better to
perform the evaluation in a per-scaffold fashion. Specifically speaking, instead of comparing
the average validity and uniqueness between models, it will be better to perform paired tests
of those metrics.
3.3.2 Molecular properties
Next, the distributions of molecular properties for generated molecules are analyzed and
compared with that in the test set. The results are summarized in Figure 10. Each point in
the scatter point corresponds to a scaffold in the test set. Its horizontal coordinate indicates
the statistics (mean or standard deviation) of a molecular property (MW, LogP or QED) of
generated molecules, while its y coordinate indicates that statistics for the test set molecules.
Scaffolds having more than 400 corresponding molecules in the test set are lighted in blue.
We first examine the mean statistics of molecular properties. Form Figure 10, it can be
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Figure 10: Comparing the distribution of several molecular properties (MW, LogP and
QED) between generated and test set molecules. For each subplot, the horizontal coordinate
indicates the statistics (a-c for mean and d-f for standard deviation) of a molecular property
(a and d for MW, b and e for LogP, c and f for QED) of generated molecules, while its y
coordinate indicates that statistics for the test set molecules. Scaffolds with more than 400
corresponding molecules (that is, |M(s)| > 400) are highlighted in blue.
observed that, for all three properties, the points in the scatter plot lies relatively close to
the diagonal line, demonstrating that the model is performing well in modeling the means
of those properties. It is also noted that scaffolds with more molecules (highlighted in blue)
lies much closer to the diagonal line compared with other scaffolds. This may indicate better
performance in scaffolds with more data points.
However, in terms of standard deviation, there is a large discrepancy between the gen-
erated and test samples. It is observed that a large number of data points lies below the
diagonal line, which indicates that the generated molecule usually have a more dispersed
distribution of molecular properties. This is ,in fact, a result of higher structural diversity
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of output molecules, as is shown in Section 3.3.3. Again, highlighted points are observed to
lie much closer to the diagnal line, showing that the model performs much better on those
scaffolds compared with the rest.
3.3.3 Molecule diversity
We subsequently analyze the internal diversity of the sampled and test set molecules, with
results summarized in Figure 11. Similar to the result showed in Figure 11, we have observed
that most data points lie below the diagonal line, indicating a higher structural diversity of
sampled molecules compared with test set molecules. Also, a similar result is observed
that scaffolds with more data in the training set perform much better compared with other
scaffolds (see the data points highlighted in blue).
3.3.4 MMD
The result for MMD is shown in Figure 11. The grey curve shows the distribution of MMD
among all test set scaffolds, while the blue curve shows the distribution of MMD among
scaffolds with more than 400 related molecules. It can be immediately observed from the
figure that the model performs significantly better for scaffolds included in the blue line.
Figure 11: Internal diversity and MMD. a. Comparing the internal diversity between gener-
ated molecules and testset molecules. Scaffolds with more than 400 corresponding molecules
(that is, |M(s)| > 400) are highlighted in blue. b. Scaffolds with high output diversity. c.
The distribution of MMD among all scaffolds in the test set. Scaffolds with more than 400
corresponding molecules are highlighted in blue.
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3.3.5 Analyzing bad-cases
In summary, the evaluation results reported in the above sections lead to the following
conclusions regarding the model’a performance:
• With a given scaffold, molecules generated by the model tend to be more structurally
diverse compared with the molecules containing that scaffold in the test set
• The distribution of generated molecules matches better with that of the test set
molecules for scaffolds that occurs more frequently.
In order to get a better understand those phenomenons, we performed a bad-case analy-
sis considering scaffolds with lowest MMD values, as demonstrated in Figure 12. Generated
molecules for those scaffolds are shown in Figure 12, while molecules containing those scaf-
folds in the test set are shown in Figure 12.
As we examine the results in Figure 12, we can immediately notice the low structural
diversity for the test set molecules. Interestingly, after inspecting the origin of those molecules
in the ChEMBL dataset, we found that those molecules are mostly collected from a single
publication or a single assay: All molecules containing scaffold 9 is originated from the assay
CHEMBL3707834, and all molecules containing scaffold 10 is originated from the assay
CHEMBL3705917. 89% of molecules containing scaffold 11 is collected from the publication
CHEMBL1144160. In other words, for each scaffold shown in Figure 12, its corresponding
molecules are largely designed by the same group of researchers under a same target.
The observations above can offer an explanation to the seemly bad performance of the
model. It can be concluded that the test set for scaffold 9-11 suffers from the non-random-
sampling bias: the molecules is sampled from a much more restricted chemical space that
reflects the preference of specific research or publication. Therefore, the performance of the
model will be underestimated, resulting in high MMD values, as well as large discrepancy
between structural and property distributions. On the contrary, a higher diversity among
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Figure 12: Demonstration of several bad-cases drawn from the test set scaffolds.
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generated molecule is a sign that the model did not memorize the side-chain distribution for
each scaffold, indicating high generalizability.
The foregoing discussion proposes a challenge for model evaluation in scaffold-diversification
tasks. In order to obtain a good assessment for the model’s performance, it is necessary to
use a test set that is unbiased in molecule distribution. Future research may explore the po-
tential of developing an unbiased benchmark set for scaffold-diversification models. Another
solution would be introducing sample weight during evaluation to mitigate the non-random-
sampling bias, which will be left for future researches.
3.3.6 Case study: privileged scaffolds for GPCRs
As described in Section 2.4.2, three privileged scaffolds for GPCRs (shown in Figure 13) are
selected for the case study. We performed leave-one-out evaluation for each scaffold, with
the results summarized in Table 2 and Figure 13.
The model performs well on the percentage of valid outputs, with values closing to 100%.
The uniqueness for scaffold 12 and 13 is 86.6% and 87.7% respectively, while for 14, the
value is of 45.4%. This smaller value might result from the higher structural complexity
of scaffold 14, which may restrict the chemical space of the side chains. Similar to the
results demonstrated in Section 3.3.2 and Section 3.3.3 generated molecules have a wider
distribution of MW, LogP and QED, and is more structurally diverse compared to real
samples. In terms of MMD, we found that scaffold 14 have a significantly lower MMD value
compared with scaffold 12 and 13. The high MMD value can largely be contributed to the
non-random-sampling bias in the test set. In fact, most scaffold containing scaffold 14 is
collected from two publications (ChEMBL id: CHEMBL1008329, CHEMBL1001157), with
both publications focusing on the same target called Neuropeptide Y receptor type 5 (NPY
Y5).
Next, we investigate the ability for the model to reproduce know active molecules against
GPCRs (see results in Table 2). Within 10,000 samples, the model can reproduce 5.17%
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Figure 13: Generated samples and reproduced active molecules. This figure shows the
generated molecules by the model given each scaffold (a. for scaffold 12, b. for scaffold 13,
c. for scaffold 14) as well as the reproduced drugs and active molecules.
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active molecules and 12.8% known drugs containing scaffold 12, 8.44% active molecules and
25% known drugs containing scaffold 13, as well as 15.9%active molecules containing scaffold
14. Several reproduced drugs are shown in Figure 13. Since the model has no access to those
molecules during the training phase, the results above demonstrated good potential for drug
discovery based on privileged scaffolds.
Table 2: Case study: privileged scaffolds for GPCRs
Scaffold 12 Scaffold 13 Scaffold 14
Diversity 0.166 0.187 0.485
Molecular Weight 363.6 (58.1) 384.9 (64.6) 385.3 (38.0)
LogP 4.04 (1.06) 4.01 (1.02) 3.72 (0.698)
QED 0.675 (0.114) 0.708 (0.121) 0.660 (0.0492)
MMD 0.0185 0.00875 0.154
R(actives) 0.0517 0.0844 0.159
R(drugs) 0.128 0.25 -
P valids 0.986 0.974 0.989
P uniqs 0.866 0.877 0.454
3.3.7 Analyzing the structural distribution of side chains
Finally, we investigate the structural distribution of side chains generated by the model. We
summarize the result in 14.
The result demonstrated a diversified substitution pattern generated from the model.
Note that for scaffold 14, the substitution only happens in location 3 for molecules inside
ChEMBL (the reason for the low diversity is discussed in Section 3.3.5). But in the generated
molecules, the substitution pattern is much more diverse, demonstrating high generalizability
for the model.
Interestingly, it is found that the model adds side-chain to nitrogen atoms more often
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Figure 14: The distribution of side chain properties at each location for scaffold 12-14.
than other locations. It is also fond the size of side-chain attached to nitrogen atoms tends
to be much larger compared with that in other positions. Those observations could be result
from a mixed effect of synthetic accessibility and drug-likeness.
3.3.8 Distribution of docking scores
The distribution of docking scores of generated molecules with DRD2 is shown in Figure
15. As demonstrated, the predicted activities of generated samples (orange) are similar
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Figure 15: The distribution of docking scores. This plot shows the distribution of docking
scores of three sets of molecules (active molecules, generated molecules, test set molecules
and random compounds from ChEMBL) for each scaffold (a. scaffold 12, b. scaffold 13
and c. scaffold 14).
to that of the test set molecules (light grey). For scaffold 13 and scaffold 14, the pre-
dicted activity against DRD2 for generated samples are significantly higher compared with
randomly sampled molecules from ChEMBL, showing that the model is good at utilizing
privileged structures for generating bioactive molecules. On the other hand, for scaffold 12,
the predicted activities of generated samples could not outperform that of random ChEMBL
samples. This may comes from the fact that the bioactivity privilege of scaffold 12 is not
as significant compared with 13 and 14, according to the docking result. In fact, scaffold
12 is highly prevalent among molecules in ChEMBL, and could occur in compounds with
different targets. This may explain the results for scaffold 12 shown above.
4 Conclusion
We proposed a comprehensive solution for scaffold-based drug discovery using deep learning.
The model is capable of performing molecular design tasks based on a wide spectrum of
scaffold definitions, including BM-scaffolds, cyclic skeletons, as well as scaffolds with speci-
fications on side-chain properties. Evaluation is performed to access the performance of the
models. In addition, we choose several privileged scaffolds for GPCRs for the case study,
demonstrating the practical value of the model in medicinal chemical problems. We intend
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to make this tool freely available for academical purposes. Please contact the authors for
licensing information.
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